Targeted massively parallel sequencing in the management of evaluated as cytogenetically normal lymphoid malignancies
Küçük Resim Yok
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Zerbinis Publications
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
The variations in clinical and biological background of lymphoid malignancies trigger researchers to try to find out novel therapeutic targets. A typical treatment includes multiagent chemotherapy and/or targeted therapy in the light of driver mutations. Next generation sequencing (NGS) plays a pivotal role during the identification of genetic alterations in lymphoid malignancies. A total of 52 patients [30 men (58%) and 22 women (42%)] having normal cytogenetic and FISH results were enrolled in this study. Usage of NGS based targeted sequencing can confirm or support a particularly preferred diagnosis (41/52, 78%) or make a differential diagnosis in cases of interference. Notably, in 11 out of these 52 cases (21%), the initial suspect diagnosis was not supported by the NGS result and thereby had to be reconsidered. In this study, we highlight the importance of targeted NGS panel testing for diagnosis, prognosis and treatment decision in highly selected instances of lymphoid malignancies and lymphoproliferative disorders in which histopathology and more conventional molecular analyses remain inconclusive. © 2021 Zerbinis Publications. All rights reserved.
Açıklama
Anahtar Kelimeler
Lymphoid Malignancies; Ngs; Targeted Therapy, Atm Protein; Azacitidine; Bendamustine; Bevacizumab; Bloom Syndrome Helicase; Brca2 Protein; Calreticulin; Cd135 Antigen; Checkpoint Kinase 2; Cyclin Dependent Kinase Inhibitor 2a; Cyclophosphamide; Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine; Dasatinib; Decitabine; E1a Associated P300 Protein; Everolimus; F Box/Wd Repeat Containing Protein 7; Gamma Secretase Inhibitor; Glucocorticoid; Interleukin 7 Receptor; Janus Kinase 1; Janus Kinase Inhibitor; Lenalidomide; Mitoxantrone; Notch1 Receptor; Olaparib; Palbociclib; Pazopanib; Phf6 Protein; Pladienolide; Prednisolone; Protein P53; Rituximab; Ruxolitinib; Selinexor; Sorafenib; Srsf2 Protein; Stag2 Protein; Sunitinib; Telomerase Reverse Transcriptase; Temsirolimus; Tet2 Protein; Tofacitinib; Trametinib; Tuba3c Protein; Unclassified Drug; Acute Lymphoblastic Leukemia; Adult; Amplicon; Article; Cancer Combination Chemotherapy; Cancer Diagnosis; Cancer Prognosis; Cancer Therapy; Chronic Lymphatic Leukemia; Clinical Decision Making; Cytogenetics; Differential Diagnosis; Diffuse Large B Cell Lymphoma; Female; Fluorescence In Situ Hybridization; Follow Up; Gene Frequency; Genetic Variability; Genetic Variation; High Throughput Sequencing; Histopathology; Hodgkin Disease; Human; Indel Mutation; Karyotype; Lymphoma; Lymphoproliferative Disease; Major Clinical Study; Male; Marginal Zone Lymphoma; Missense Mutation; Molecularly Targeted Therapy; Nonhodgkin Lymphoma; Oncogene N Ras; Personalized Medicine; Adolescent; Aged; Child; Chromosome Analysis; Genetics; High Throughput Sequencing; Infant; Leukemia; Lymphoma; Middle Aged; Preschool Child; Procedures; Retrospective Study; Young Adult; Adolescent; Adult; Aged; Child; Child, Preschool; Cytogenetic Analysis; Female; High-Throughput Nucleotide Sequencing; Humans; Infant; Leukemia; Lymphoma; Male; Middle Aged; Retrospective Studies; Young Adult
Kaynak
Journal of B.U.ON.
WoS Q Değeri
Scopus Q Değeri
Q3
Cilt
26
Sayı
4
